Clatterbridge Cancer Centre Papillon+ Training a Strong Success

28th March 2026
Clatterbridge Cancer Centre Papillon+ Training a Strong Success
The Liner Hotel, Liverpool | 25th–26th March 2026

The first of two Papillon+ training events scheduled for 2026 was successfully delivered at The Liner Hotel, hosted by Arthur Sun Myint and Jean Pierre Gérard.

The two-day event welcomed clinicians and specialists from across Great Britain and North America, reflecting the growing international interest in Papillon+ technology.

Momentum has continued to build following the National Institute for Health and Care Excellence (NICE) approval on 13th November 2025. NICE now recommends Contact X-ray Brachytherapy (CXB) for selected lower rectal cancer patients, including operable cases with tumours up to T3a–b. These updated guidelines represent a significant step forward, offering more patients the opportunity for organ preservation and non-invasive treatment options.

A key focus of the training was the OPERA Trial, alongside wider discussion on the evolving “watch and wait” approach in rectal cancer management.

The event also benefited from multidisciplinary input, with valuable contributions from surgical teams, radiation oncology specialists, and medical physics professionals.

With both clinical outcomes and healthcare economics under increasing scrutiny, Papillon+ is continuing to establish itself as a credible alternative to conventional surgery—particularly in improving post-treatment quality of life.

Following NICE approval, momentum in the UK continues to accelerate. Several clinical trials are now in the pipeline, with an additional 8–10 installations expected across treatment centres of excellence by the end of 2026.